Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better.

Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Our Family of Companies comprises:

  • The world’s sixth-largest consumer health company
  • The world’s largest and most diverse medical devices company
  • The world’s sixth-largest biologics company
  • And the world’s fifth-largest pharmaceuticals company

We have more than 265 operating companies in more than 60 countries.

Company Growth (employees)
New Brunswick, US
Size (employees)
126,400 (est)
Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, US

Key People at Johnson & Johnson

Alex Gorsky

Alex Gorsky

Dominic J. Caruso

Dominic J. Caruso

Ronald A. Williams

Ronald A. Williams

Independent Director
Michael Sneed

Michael Sneed

VP, Global Corporate Affairs
Peter Fasolo

Peter Fasolo

Executive VP, CHRO
Paul Stoffels

Paul Stoffels

Executive VP & CSO

Johnson & Johnson Office Locations

Johnson & Johnson has an office in New Brunswick
New Brunswick, US (HQ)
One Johnson & Johnson Plaza

Johnson & Johnson Metrics

Johnson & Johnson Financial Metrics

Revenue (2016)

$71.9 b

Revenue growth (2015-16), %


Gross profit

$50.2 b

Gross profit margin (2016), %


Net income (2016)

$16.5 b

Market capitalization (21-Mar-2017)

$346.3 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$19 b
Johnson & Johnson's current market capitalization is $346.3 b.
Johnson & Johnson's revenue was reported to be $71.9 b in FY, 2016 which is a 2.6% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$71.3 b$74.3 b$70.1 b$71.9 b

Revenue growth, %


Cost of goods sold

$22.3 b$22.7 b$21.5 b$21.7 b

Gross profit

$49 b$51.6 b$48.5 b$50.2 b

Gross profit Margin, %


Sales and marketing expense

$21.8 b$22 b$21.2 b$19.9 b

R&D expense

$8.2 b$8.5 b$9 b$9.1 b

Operating expense total

$30 b$30.4 b$30.2 b$29 b

Depreciation and amortization

$4.1 b$3.9 b$3.7 b$3.8 b


$16.4 b$21.6 b$19.2 b$16.5 b

EBIT margin, %


Interest expense

$580 m$533 m$552 m$726 m

Interest income

$74 m$67 m$128 m$368 m

Pre tax profit

$15.5 b$20.6 b$19.2 b$19.8 b

Income tax expense

$1.6 b$4.2 b$3.8 b$3.3 b

Net Income

$13.8 b$16.3 b$15.4 b$16.5 b
Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016


$15.8 b$19.4 b$24.5 b$20.9 b$14.5 b$13.7 b$19 b


$7.9 b$8.2 b$8.1 b$8.1 b

Current Assets

$56.4 b$59.3 b$60.2 b$65 b


$16.7 b$16.1 b$15.9 b$15.9 b


$22.8 b$21.8 b$21.6 b$22.8 b

Total Assets

$132.7 b$131.1 b$133.4 b$141.2 b

Accounts Payable

$6.3 b$7.6 b$6.7 b$6.9 b

Total Debt

$13.3 b$15.1 b$12.9 b$22.4 b

Current Liabilities

$25.7 b$25.1 b$27.7 b$26.3 b

Retained Earnings

$89.5 b$97.2 b$103.9 b$110.6 b

Total Equity

$71.2 b$70.4 b

Debt to Equity Ratio

0.2 x0.3 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x

Financial Leverage

1.9 x2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$13.8 b$16.3 b$15.4 b$16.5 b

Accounts Receivable

($632 m)($247 m)($433 m)($1.1 b)


($622 m)($1.1 b)($449 m)($249 m)

Accounts Payable

$1.8 b$955 m$656 m

Cash From Operating Activities

$17.4 b$18.5 b$19.3 b$18.8 b

Purchases of PP&E

($3.6 b)($3.7 b)($3.5 b)($3.2 b)

Cash From Investing Activities

($5.1 b)($12.3 b)($7.7 b)($4.8 b)

Interest Paid

$596 m$603 m$515 m$730 m

Income Taxes Paid

$3.2 b$3.5 b$2.9 b$2.8 b

Johnson & Johnson Operating Metrics

FY, 2014FY, 2015FY, 2016

Discovery Projects




Drugs Approved by FDA


Johnson & Johnson Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Actelion PharmaceuticalsJanuary 26, 2017$30 b
Abott Medical OpticsSeptember 16, 2016$4.3 b
Vogue InternationalJune 02, 2016$3.3 b
Novira TherapeuticsNovember 08, 2015
XO1March 20, 2015
Alios BioPharmaSeptember 30, 2014$1.8 b
Aragon PharmaceuticalsJune 17, 2013$1 b

Johnson & Johnson Market Value History

Johnson & Johnson Revenue Breakdown

Johnson & Johnson Median Salaries

Source: 32 public H-1B filings from Johnson & Johnson

Johnson & Johnson Online Presence

Johnson & Johnson Company Life

You may also be interested in